scholarly journals Bromocriptine for the Treatment of Peripartum Cardiomyopathy

2018 ◽  
Vol 4 (1) ◽  
pp. 1 ◽  
Author(s):  
Tobias Koenig ◽  
Johann Bauersachs ◽  
Denise Hilfiker-Kleine
Keyword(s):  
Peripartum Cardiomyopathy

scholarly journals Prognostic value of NT-proBNP for myocardial recovery in peripartum cardiomyopathy (PPCM)

2021 ◽  
Author(s):  
J. Hoevelmann ◽  
E. Muller ◽  
F. Azibani ◽  
S. Kraus ◽  
J. Cirota ◽  
...  
Keyword(s):  
Prognostic Value ◽  
Systolic Function ◽  
Point Of Care ◽  
Diagnostic Value ◽  
Left Ventricular ◽  
Peripartum Cardiomyopathy ◽  
Lv Function ◽  
Myocardial Recovery ◽  
End Diastolic Volume

Abstract Introduction Peripartum cardiomyopathy (PPCM) is an important cause of pregnancy-associated heart failure worldwide. Although a significant number of women recover their left ventricular (LV) function within 12 months, some remain with persistently reduced systolic function. Methods Knowledge gaps exist on predictors of myocardial recovery in PPCM. N-terminal pro-brain natriuretic peptide (NT-proBNP) is the only clinically established biomarker with diagnostic value in PPCM. We aimed to establish whether NT-proBNP could serve as a predictor of LV recovery in PPCM, as measured by LV end-diastolic volume (LVEDD) and LV ejection fraction (LVEF). Results This study of 35 women with PPCM (mean age 30.0 ± 5.9 years) had a median NT-proBNP of 834.7 pg/ml (IQR 571.2–1840.5) at baseline. Within the first year of follow-up, 51.4% of the cohort recovered their LV dimensions (LVEDD < 55 mm) and systolic function (LVEF > 50%). Women without LV recovery presented with higher NT-proBNP at baseline. Multivariable regression analyses demonstrated that NT-proBNP of ≥ 900 pg/ml at the time of diagnosis was predictive of failure to recover LVEDD (OR 0.22, 95% CI 0.05–0.95, P = 0.043) or LVEF (OR 0.20 [95% CI 0.04–0.89], p = 0.035) at follow-up. Conclusions We have demonstrated that NT-proBNP has a prognostic value in predicting LV recovery of patients with PPCM. Patients with NT-proBNP of ≥ 900 pg/ml were less likely to show any improvement in LVEF or LVEDD. Our findings have implications for clinical practice as patients with higher NT-proBNP might require more aggressive therapy and more intensive follow-up. Point-of-care NT-proBNP for diagnosis and risk stratification warrants further investigation.

scholarly journals Women with peripartum cardiomyopathy have normal ejection fraction, but abnormal systolic strain, during pregnancy

2021 ◽  
Author(s):  
Ruth Tamrat ◽  
Yu Kang ◽  
Marielle Scherrer‐Crosbie ◽  
Lisa D. Levine ◽  
Zoltan Arany ◽  
...  
Keyword(s):  
Ejection Fraction ◽  
Peripartum Cardiomyopathy ◽  
Normal Ejection Fraction ◽  
Systolic Strain

scholarly journals Disparities in clinical features and outcomes of peripartum cardiomyopathy in high versus low prevalent regions in Nigeria

2021 ◽  
Author(s):  
Kamilu M. Karaye ◽  
Naser A. Ishaq ◽  
Hadiza Sai'du ◽  
Sulaiman A. Balarabe ◽  
Bashir G. Ahmed ◽  
...  
Keyword(s):  
Clinical Features ◽  
Peripartum Cardiomyopathy
Sign in / Sign up

Export Citation Format

Share Document